Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2026CancersOpen Access

Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

XNXiao NiWHWei HanNKNiharika Kunta

Discussion

Loading...

Member takes

Overview

Randomized trial investigates immune features relating to treatment outcomes in cutaneous T-cell lymphoma, suggesting new biomarkers for therapy.

Key Points

  • The study aims to investigate immune determinants affecting treatment response in cutaneous T-cell lymphoma during mogamulizumab therapy.
  • Characterized immune and structural elements in FFPE tissues from 16 cutaneous T-cell lymphoma patients using imaging mass cytometry.
  • Performed single-cell phenotyping and spatial analyses with Visiopharm® Phenoplex™ platform.
  • Identified immune components and their associations with treatment responses for MF and SS patients.
  • Malignant CD4+ T cells showed reduced expression of CD27, CD103, CD25, and ICOS compared to non-malignant CD4+ cells.
  • Baseline MF lesions had a higher presence of IL-13+ and CD103+ malignant T cells, while SS lesions showed more CD27+ and LAG3+ cells.
  • Increased M1-like macrophages correlated with responders, while non-responders displayed fewer M1-like features.

Cite This Study

Ni et al. (2026) studied this question.

synapsesocial.com/papers/6a61af8bfaa9903c5116a45chttps://doi.org/10.3390/cancers18142348
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune Dysregulation, Compartment-Specific Biology, and Therapeutic Biomarkers in Mycosis Fungoides and Sézary Syndrome2026
  2. 2Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment2026
  3. 3Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon2024 · 2 citations
  4. 4Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases2024 · 7 citations
  5. 5Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides2025 · 1 citations